Related references
Note: Only part of the references are listed.Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Danling Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
H. Yesid Estupinan et al.
LEUKEMIA (2021)
Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
Saul Jaime-Figueroa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
Ronen Gabizon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George et al.
CANCERS (2020)
Unifying principles of bifunctional, proximity-inducing small molecules
Christopher J. Gerry et al.
NATURE CHEMICAL BIOLOGY (2020)
Understanding and Improving the Membrane Permeability of VH032-Based PROTACs
Victoria G. Klein et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Wen-Hao Guo et al.
NATURE COMMUNICATIONS (2020)
Protein degradation through covalent inhibitor-based PROTACs
Gang Xue et al.
CHEMICAL COMMUNICATIONS (2020)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges
Scott D. Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of targeted protein degradation therapeutics
Philip P. Chamberlain et al.
NATURE CHEMICAL BIOLOGY (2019)
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding
Christopher P. Tinworth et al.
ACS CHEMICAL BIOLOGY (2019)
A MedChem toolbox for cereblon-directed PROTACs
Christian Steinebach et al.
MEDCHEMCOMM (2019)
PROTAC-mediated crosstalk between E3 ligases
Christian Steinebach et al.
CHEMICAL COMMUNICATIONS (2019)
Developing degraders: principles and perspectives on design and chemical space
Hannah J. Maple et al.
MEDCHEMCOMM (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D. Reiff et al.
CANCER DISCOVERY (2018)
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies
Caspar da Cunha-Bang et al.
DRUGS (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia
Sean D. Reiff et al.
BLOOD (2016)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Share Paper
